{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:27Z","timestamp":1791215187711,"version":"4.1.0"},"reference-count":33,"publisher":"The Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["31003A-179400"],"award-info":[{"award-number":["31003A-179400"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC\/Transregio 205\/1"],"award-info":[{"award-number":["CRC\/Transregio 205\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2013_A182"],"award-info":[{"award-number":["2013_A182"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2015_A171"],"award-info":[{"award-number":["2015_A171"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","award":["DBZ8682"],"award-info":[{"award-number":["DBZ8682"]}],"id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung f\u00fcr Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","award":["16A019"],"award-info":[{"award-number":["16A019"]}],"id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Mammalian target of rapamycin complex 1 (mTORC1) activity is often increased in the adrenal cortex of patients with primary aldosteronism (PA), and mTORC1 inhibition decreases aldosterone production in adrenocortical cells, suggesting the mTORC1 pathway as a target for treatment of PA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the effect of mTORC1 inhibition on adrenal steroid hormones and hemodynamic parameters in mice and in patients with PA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>(i) Plasma aldosterone, corticosterone, and angiotensin II (Ang II) were measured in mice treated for 24 hours with vehicle or rapamycin. (ii) Plasma aldosterone levels after a saline infusion test, plasma renin, and 24-hour urine steroid hormone metabolome and hemodynamic parameters were measured during an open-label study in 12 patients with PA, before and after 2 weeks of treatment with everolimus and after a 2-week washout.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>(i) Change in plasma aldosterone levels. (ii) Change in other steroid hormones, renin, Ang II, and hemodynamic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Treatment of mice with rapamycin significantly decreased plasma aldosterone levels (P = 0.007). Overall, treatment of PA patients with everolimus significantly decreased blood pressure (P &lt; 0.05) and increased renin levels (P = 0.001) but did not decrease aldosterone levels significantly. However, prominent reduction of aldosterone levels upon everolimus treatment was observed in four patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In mice, mTORC1 inhibition was associated with reduced plasma aldosterone levels. In patients with PA, mTORC1 inhibition was associated with improved blood pressure and renin suppression. In addition, mTORC1 inhibition appeared to reduce plasma aldosterone in a subset of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-00563","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T09:10:06Z","timestamp":1557825006000},"page":"4703-4714","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Primary Aldosteronism With mTORC1 Inhibitors"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-7079","authenticated-orcid":false,"given":"Beckey","family":"Trinh","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-6235","authenticated-orcid":false,"given":"Matthias","family":"Hepprich","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-1871","authenticated-orcid":false,"given":"Matthias J","family":"Betz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6373-9820","authenticated-orcid":false,"given":"Thilo","family":"Burkard","sequence":"additional","affiliation":[{"name":"European Society of Hypertension Centre of Excellence, Medical Outpatient Department, and Department of Cardiology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0650-6091","authenticated-orcid":false,"given":"Claudia","family":"Cavelti-Weder","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-1986","authenticated-orcid":false,"given":"Eleonora","family":"Seelig","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-8491","authenticated-orcid":false,"given":"Fabian","family":"Meienberg","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology and Diabetology, Kantonsspital Baselland, Liestal, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise V","family":"Kratschmar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3984","authenticated-orcid":false,"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Endokrinologie, Diabetologie und Klinische Ern\u00e4hrung, Universit\u00e4tsspital Z\u00fcrich, Z\u00fcrich, Switzerland"},{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-2712","authenticated-orcid":false,"given":"Alex","family":"Odermatt","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N","family":"Hall","sequence":"additional","affiliation":[{"name":"Biozentrum, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3143-5045","authenticated-orcid":false,"given":"Marc Y","family":"Donath","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, and Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M","family":"Swierczynska","sequence":"additional","affiliation":[{"name":"Biozentrum, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"3","key":"2019091012184081500_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0031-1295438","article-title":"Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2014a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"issue":"5","key":"2019091012184081500_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019091012184081500_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2019091012184081500_bib4","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019091012184081500_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"issue":"22","key":"2019091012184081500_bib6","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"2019091012184081500_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019091012184081500_bib8","doi-asserted-by":"crossref","first-page":"32103","DOI":"10.1038\/srep32103","article-title":"Long term outcome of aldosteronism after target treatments [published correction appears in Sci Rep. 2017;7:45249]","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"2019091012184081500_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/1470320314549220","article-title":"Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism","volume":"16","author":"Indra","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"2019091012184081500_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ackd.2014.10.003","article-title":"Outcomes of drug-based and surgical treatments for primary aldosteronism","volume":"22","author":"Steichen","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"2019091012184081500_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fendo.2015.00095","article-title":"Molecular and cellular mechanisms of aldosterone producing adenoma development","volume":"6","author":"Boulkroun","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2019091012184081500_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coph.2014.12.005","article-title":"The molecular basis of primary aldosteronism: from chimeric gene to channelopathy","volume":"21","author":"Lenzini","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"2019091012184081500_bib13","doi-asserted-by":"crossref","first-page":"e62399","DOI":"10.1371\/journal.pone.0062399","article-title":"The PI3K\/AKT\/mTOR signaling pathway is overactivated in primary aldosteronism","volume":"8","author":"Su","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2019091012184081500_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/ERC-11-0270","article-title":"The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells","volume":"19","author":"De Martino","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2019091012184081500_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/ERC-11-0337","article-title":"Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models","volume":"19","author":"Mariniello","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"2019091012184081500_bib16","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1093\/hmg\/ddu265","article-title":"mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD)","volume":"23","author":"de Joussineau","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2019091012184081500_bib17","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1158\/0008-5472.CAN-09-3970","article-title":"Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors","volume":"70","author":"Doghman","year":"2010","journal-title":"Cancer Res"},{"key":"2019091012184081500_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tox.2017.02.010","article-title":"Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids","volume":"381","author":"Strajhar","year":"2017","journal-title":"Toxicology"},{"issue":"2","key":"2019091012184081500_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.118.11733","article-title":"Proteomic landscape of aldosterone-producing adenoma","volume":"73","author":"Swierczynska","year":"2019","journal-title":"Hypertension"},{"issue":"5","key":"2019091012184081500_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00004872-200305000-00001","article-title":"European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement","volume":"21","author":"O\u2019Brien","year":"2003","journal-title":"J Hypertens"},{"issue":"4","key":"2019091012184081500_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1530\/EJE-11-0914","article-title":"Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients","volume":"166","author":"Solar","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019091012184081500_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/ERC-13-0112","article-title":"Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors","volume":"21","author":"De Martino","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2019091012184081500_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"2","key":"2019091012184081500_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cmet.2017.07.001","article-title":"The dawn of the age of amino acid sensors for the mTORC1 pathway","volume":"26","author":"Wolfson","year":"2017","journal-title":"Cell Metab"},{"issue":"10","key":"2019091012184081500_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/ERC-17-0117","article-title":"Molecular characteristics of the KCNJ5 mutated aldosterone-producing adenomas","volume":"24","author":"Murakami","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"13","key":"2019091012184081500_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0035-1565198","article-title":"Bilateral idiopathic adrenal hyperplasia: genetics and beyond","volume":"47","author":"Zennaro","year":"2015","journal-title":"Horm Metab Res"},{"issue":"4","key":"2019091012184081500_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/HYPERTENSIONAHA.113.02234","article-title":"Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism","volume":"63","author":"Murthy","year":"2014","journal-title":"Hypertension"},{"issue":"7","key":"2019091012184081500_bib28","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"2019091012184081500_bib29","doi-asserted-by":"crossref","first-page":"E1736","DOI":"10.3390\/ijms18081736","article-title":"Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Bendtsen","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2019091012184081500_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cmet.2013.02.017","article-title":"Hypothalamic mTORC1 signaling controls sympathetic nerve activity and arterial pressure and mediates leptin effects","volume":"17","author":"Harlan","year":"2013","journal-title":"Cell Metab"},{"issue":"1","key":"2019091012184081500_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"2019091012184081500_bib32","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence adnd clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"667","key":"2019091012184081500_bib33","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.3399\/bjgp18X694589","article-title":"Prevalence of primary aldosteronism in primary care: a cross-sectional study","volume":"68","author":"K\u00e4yser","year":"2018","journal-title":"Br J Gen Pract"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00563\/28599658\/jc.2019-00563.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/10\/4703\/29643073\/jc.2019-00563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T23:43:37Z","timestamp":1569109417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/10\/4703\/5488074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00563","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,5,14]]}}}